Yanan Zhu
Stock Analyst at Wells Fargo
(1.02)
# 3,504
Out of 4,829 analysts
75
Total ratings
25%
Success rate
-10.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $115 → $100 | $36.37 | +174.95% | 2 | May 8, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $75 → $70 | $18.22 | +284.19% | 3 | May 7, 2025 | |
| RGLS Regulus Therapeutics | Downgrades: Equal-Weight | $9 | $7.87 | +14.36% | 2 | May 1, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $2 → $1.5 | $0.30 | +408.13% | 2 | Mar 21, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $8 → $6 | $1.35 | +344.44% | 3 | Mar 21, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $25 → $20 | $1.55 | +1,190.32% | 2 | Mar 18, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Overweight | $12 → $10 | $3.35 | +198.95% | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $58 → $50 | $11.59 | +331.41% | 6 | Mar 7, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $5 → $4 | $1.07 | +273.83% | 3 | Mar 6, 2025 | |
| QURE uniQure | Maintains: Equal-Weight | $35 → $30 | $13.15 | +128.14% | 2 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $50 | $8.55 | +484.80% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $5 | $3.29 | +51.98% | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $15 | $0.69 | +2,064.50% | 6 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $4 | $1.54 | +159.74% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $4 | $0.88 | +356.41% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $77 | $33.53 | +129.65% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $14.92 | +168.10% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $37.59 | +72.92% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.85 | +952.63% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $1.93 | +1,195.34% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $29.33 | +70.47% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.75 | +435.62% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.91 | +15,363.92% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $2.32 | +331.03% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $560.90 | -41.88% | 1 | Feb 2, 2021 |
Sarepta Therapeutics
May 8, 2025
Maintains: Overweight
Price Target: $115 → $100
Current: $36.37
Upside: +174.95%
Beam Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $18.22
Upside: +284.19%
Regulus Therapeutics
May 1, 2025
Downgrades: Equal-Weight
Price Target: $9
Current: $7.87
Upside: +14.36%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.30
Upside: +408.13%
Autolus Therapeutics
Mar 21, 2025
Maintains: Overweight
Price Target: $8 → $6
Current: $1.35
Upside: +344.44%
Metagenomi
Mar 18, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $1.55
Upside: +1,190.32%
Voyager Therapeutics
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.35
Upside: +198.95%
Arcturus Therapeutics Holdings
Mar 7, 2025
Maintains: Overweight
Price Target: $58 → $50
Current: $11.59
Upside: +331.41%
Fate Therapeutics
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $1.07
Upside: +273.83%
uniQure
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $13.15
Upside: +128.14%
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $8.55
Upside: +484.80%
Feb 24, 2025
Maintains: Equal-Weight
Price Target: $40 → $5
Current: $3.29
Upside: +51.98%
Dec 12, 2024
Maintains: Overweight
Price Target: $20 → $15
Current: $0.69
Upside: +2,064.50%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $1.54
Upside: +159.74%
Nov 12, 2024
Maintains: Overweight
Price Target: $17 → $4
Current: $0.88
Upside: +356.41%
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $33.53
Upside: +129.65%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $14.92
Upside: +168.10%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $37.59
Upside: +72.92%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $2.85
Upside: +952.63%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $1.93
Upside: +1,195.34%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $29.33
Upside: +70.47%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.75
Upside: +435.62%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.91
Upside: +15,363.92%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $2.32
Upside: +331.03%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $560.90
Upside: -41.88%